Yu-Ting Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yu-Ting Li has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Chia-Der Lin
China Medical University Hospital
3 shared publications - Chih-Jaan Tai
Department of Otorhinolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung 404327, Taiwan
3 shared publications - Jin-Yi Lin
Department of Otorhinolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung 404327, Taiwan
3 shared publications - Liang-Chun Shih
Department of Otorhinolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung 404, Taiwan
3 shared publications - Yung-An Tsou
Department of Otorhinolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung 404327, Taiwan
2 shared publications - Zheng-Yan Dai
Department of Otorhinolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung 404327, Taiwan
2 shared publications
Latest Publications
- Open Access
- 22 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (11) , 3637
The Effect of Fluticasone Nasal Spray on Patients with Chronic Rhinitis and Chronic Obstructive Pulmonary Disease
Background: Although upper and lower respiratory tract diseases coexist, studies discussing the relationship between chronic rhinitis (CR) and chronic obstructive pulmonary disease (COPD) are limited. Fluticasone nasal sprays are common treatment options for patients with rhinitis. Therefore, we aimed to investigate the effects of fluticasone nasal spray on patients with both CR and COPD. Methods: A retrospective review was performed using data from former smokers with CR and COPD at China Medical University Hospital (CMUH). Based on their medication history, patients were allocated into Group A, who had received treatment with fluticasone nasal spray, and Group B, who had never received this treatment. Pulmonary function test results, including forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC), were collected for both groups before treatment and one year after treatment. Statistical analysis was performed to evaluate the impact of fluticasone nasal spray treatment on pulmonary function. Results: A total of 123 former smokers were included, with 62 patients in Group A and 61 patients in Group B. At baseline, there was no significant difference in age, sex, and pulmonary function between the two groups. After one year of treatment, Group A showed an upward trend in pulmonary function, with the FEV1 increasing from 1.613 ± 0.554 to 1.708 ± 0.675 (p < 0.05) and the FVC increasing from 2.540 ± 0.694 to 2.670 ± 0.839 (p < 0.05). On the other hand, Group B exhibited a downward trend in pulmonary function after one year, with the FEV1 decreasing from 1.609 ± 0.554 to 1.544 ± 0.517 (p < 0.05) and the FVC decreasing from 2.586 ± 0.665 to 2.495 ± 0.679 (p < 0.05). Conclusions: This retrospective study suggests that the combined use of fluticasone nasal spray may be associated with improved pulmonary function in former smokers with both CR and COPD. This finding supports the concept of “united airway disease”.
- 22 May 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (11) , 3637
Open AccessThe Effect of Fluticasone Nasal Spray on Patients with Chronic Rhinitis and Chronic Obstructive Pulmonary Disease
Background: Although upper and lower respiratory tract diseases coexist, studies discussing the relationship between chronic rhinitis (CR) and chronic obstructive pulmonary disease (COPD) are limited. Fluticasone nasal sprays are common treatment options for patients with rhinitis. Therefore, we aimed to investigate the effects of fluticasone nasal spray on patients with both CR and COPD. Methods: A retrospective review was performed using data from former smokers with CR and COPD at China Medical University Hospital (CMUH). Based on their medication history, patients were allocated into Group A, who had received treatment with fluticasone nasal spray, and Group B, who had never received this treatment. Pulmonary function test results, including forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC), were collected for both groups before treatment and one year after treatment. Statistical analysis was performed to evaluate the impact of fluticasone nasal spray treatment on pulmonary function. Results: A total of 123 former smokers were included, with 62 patients in Group A and 61 patients in Group B. At baseline, there was no significant difference in age, sex, and pulmonary function between the two groups. After one year of treatment, Group A showed an upward trend in pulmonary function, with the FEV1 increasing from 1.613 ± 0.554 to 1.708 ± 0.675 (p < 0.05) and the FVC increasing from 2.540 ± 0.694 to 2.670 ± 0.839 (p < 0.05). On the other hand, Group B exhibited a downward trend in pulmonary function after one year, with the FEV1 decreasing from 1.609 ± 0.554 to 1.544 ± 0.517 (p < 0.05) and the FVC decreasing from 2.586 ± 0.665 to 2.495 ± 0.679 (p < 0.05). Conclusions: This retrospective study suggests that the combined use of fluticasone nasal spray may be associated with improved pulmonary function in former smokers with both CR and COPD. This finding supports the concept of “united airway disease”.
- Open Access
- 12 April 2025
- Published by MDPI AG in Preprints.org
The Effect of Fluticasone Nasal Spray on Patients with Chronic Rhinitis and Chronic Obstructive Pulmonary Disease
Background: Although upper and lower respiratory tract diseases coexist, studies discussing the relationship between chronic rhinitis (CR) and chronic obstructive pulmonary disease (COPD) are limited. Fluticasone nasal sprays are common treatment options for patients with rhinitis. Therefore, we aimed to investigate the effects of fluticasone nasal spray on patients with both CR and COPD. Methods: A retrospective review was performed using data from former smokers with CR and COPD at China Medical University Hospital (CMUH). Based on their medication history, patients were allocated into Group A, who had received treatment with fluticasone nasal spray, and Group B, who had never received this treatment. Pulmonary function test results, including forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), were collected for both groups before treatment and one year after treatment. Statistical analysis was performed to evaluate the impact of fluticasone nasal spray treatment on pulmonary function. Results: A total of 123 former smokers were included, with 62 patients in Group A and 61 patients in Group B. At the baseline, there was no significant difference in age, sex, and pulmonary function between the two groups. After one year of treatment, Group A showed an upward trend in pulmonary function, with FEV1 increasing from 1.613 ± 0.554 to 1.708 ± 0.675 (P < 0.05) and FVC increasing from 2.540 ± 0.694 to 2.670 ± 0.839 (P < 0.05). Whereas, Group B exhibited a downward trend in pulmonary function after one year, with FEV1 decreasing from 1.609 ± 0.554 to 1.544 ± 0.517 (P < 0.05) and FVC decreasing from 2.586 ± 0.665 to 2.495 ± 0.679 (P < 0.05). Conclusions: The use of fluticasone nasal spray can improve pulmonary function in former smokers with both CR and COPD. This finding supports the "one airway, one disease" theory.
- 12 April 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Effect of Fluticasone Nasal Spray on Patients with Chronic Rhinitis and Chronic Obstructive Pulmonary Disease
Background: Although upper and lower respiratory tract diseases coexist, studies discussing the relationship between chronic rhinitis (CR) and chronic obstructive pulmonary disease (COPD) are limited. Fluticasone nasal sprays are common treatment options for patients with rhinitis. Therefore, we aimed to investigate the effects of fluticasone nasal spray on patients with both CR and COPD. Methods: A retrospective review was performed using data from former smokers with CR and COPD at China Medical University Hospital (CMUH). Based on their medication history, patients were allocated into Group A, who had received treatment with fluticasone nasal spray, and Group B, who had never received this treatment. Pulmonary function test results, including forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), were collected for both groups before treatment and one year after treatment. Statistical analysis was performed to evaluate the impact of fluticasone nasal spray treatment on pulmonary function. Results: A total of 123 former smokers were included, with 62 patients in Group A and 61 patients in Group B. At the baseline, there was no significant difference in age, sex, and pulmonary function between the two groups. After one year of treatment, Group A showed an upward trend in pulmonary function, with FEV1 increasing from 1.613 ± 0.554 to 1.708 ± 0.675 (P < 0.05) and FVC increasing from 2.540 ± 0.694 to 2.670 ± 0.839 (P < 0.05). Whereas, Group B exhibited a downward trend in pulmonary function after one year, with FEV1 decreasing from 1.609 ± 0.554 to 1.544 ± 0.517 (P < 0.05) and FVC decreasing from 2.586 ± 0.665 to 2.495 ± 0.679 (P < 0.05). Conclusions: The use of fluticasone nasal spray can improve pulmonary function in former smokers with both CR and COPD. This finding supports the "one airway, one disease" theory.
- Open Access
- 21 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (8) , 2420
Clinical Outcomes of Severe Rhinosinusitis Complicated with Cavernous Sinus Syndrome
Background: Various diseases involving the cavernous sinus can cause a condition called cavernous sinus syndrome (CSS), which is characterized by ophthalmoplegia or sensory deficits over the face resulting from the compression effect of internal structure. While tumor compression is the most reported cause of CSS, statistical data on CSS caused by infections are limited. Its risk factors, treatment methods, and clinical outcomes are not well-documented. Methods: In this retrospective study, we reviewed the data of patients admitted to a tertiary medical center from 2015 to 2022 with a diagnosis of acute and chronic sinusitis and at least one diagnostic code for CSS symptoms. We manually reviewed whether patients were involved in two or more of the following cranial nerves (CN): CN III, CN IV, CN V, or CN VI, or at least one of these nerves with a neuroimaging-confirmed lesion in the cavernous sinus. Results: Nine patients were diagnosed with rhinosinusitis-related CSS. The most common comorbidity was type 2 diabetes, and the most common clinical manifestations were diplopia and blurred vision. The sphenoid sinus was the most affected sinus. One patient expired due to a severe brain abscess infection without surgery. The remaining patients underwent functional endoscopic sinus surgery, and 50% of the pathology reports indicated fungal infections. Staphylococcus spp. was the most cultured bacteria, and Amoxycillin/Clavulanate was the most used antibiotic. Only four patients had total recovery during the follow-up one year later. Conclusions: CSS is a rare but serious complication of rhinosinusitis. Patients with diabetes and the elderly may be at a higher risk for this complication. Even after treatment, some patients may still have neurological symptoms.
- 21 April 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (8) , 2420
Open AccessClinical Outcomes of Severe Rhinosinusitis Complicated with Cavernous Sinus Syndrome
Background: Various diseases involving the cavernous sinus can cause a condition called cavernous sinus syndrome (CSS), which is characterized by ophthalmoplegia or sensory deficits over the face resulting from the compression effect of internal structure. While tumor compression is the most reported cause of CSS, statistical data on CSS caused by infections are limited. Its risk factors, treatment methods, and clinical outcomes are not well-documented. Methods: In this retrospective study, we reviewed the data of patients admitted to a tertiary medical center from 2015 to 2022 with a diagnosis of acute and chronic sinusitis and at least one diagnostic code for CSS symptoms. We manually reviewed whether patients were involved in two or more of the following cranial nerves (CN): CN III, CN IV, CN V, or CN VI, or at least one of these nerves with a neuroimaging-confirmed lesion in the cavernous sinus. Results: Nine patients were diagnosed with rhinosinusitis-related CSS. The most common comorbidity was type 2 diabetes, and the most common clinical manifestations were diplopia and blurred vision. The sphenoid sinus was the most affected sinus. One patient expired due to a severe brain abscess infection without surgery. The remaining patients underwent functional endoscopic sinus surgery, and 50% of the pathology reports indicated fungal infections. Staphylococcus spp. was the most cultured bacteria, and Amoxycillin/Clavulanate was the most used antibiotic. Only four patients had total recovery during the follow-up one year later. Conclusions: CSS is a rare but serious complication of rhinosinusitis. Patients with diabetes and the elderly may be at a higher risk for this complication. Even after treatment, some patients may still have neurological symptoms.